Viscoanesthesia. Part III: removal time of OVD/viscoanesthetic solutions from the capsular bag of postmortem human eyes

Ophthalmic viscosurgical device interaction with two hydrophobic acrylic intraocular lenses of different equilibrium water content

Ophthalmic viscosurgical device (OVD) is used during intraocular surgery to protect ocular tissue. It requires complete removal from the eye by the end of surgery to avoid postoperative complications. This study compares the interaction of a cohesive OVD with two different intraocular lenses (IOLs) of different equilibrium water content. In this laboratory study on porcine cadaver eyes, the capsular bags and anterior chambers of each eye were filled with fluorescein-stained OVD. Following implantation of 10 IOLs each of Clareon CNA0T0 and AcrySof SN60WF (Alcon Laboratory, Fort Worth, USA) IOLs, the OVD was removed using the irrigation/aspiration mode. The OVD removal was timed and differences between the both IOL groups were compared. OVD removal time ranged from 18 to 40 s (mean ± SD, 26.4 ± 6.8 s) and from 16 to 39 s (mean ± SD, 23.6 ± 6.6 s) for eyes implanted with a CNA0T0 and a SN60WF IOL, respectively, without a statistically significant difference between the groups, P > 0.05. Cohesive OVD removal times were similar between the CNA0T0 and SN60WF groups. Surgeons should experience no differences regarding the interaction between cohesive OVDs and IOLs made from the new Clareon material compared to the established AcrySof material.

Ophthalmic Viscosurgical Devices (OVDs) in Challenging Cases: a Review

Ophthalmic viscoelastic devices (OVDs) are currently used in cataract surgery and have significantly improved the safety and effectiveness of this surgical procedure. OVDs are classified according to the zero-shear viscosity and the cohesion-dispersion index in cohesive, dispersive, and viscoadaptives. OVDs create and maintain anterior chamber depth and visibility, protecting the corneal endothelium and other intraocular tissues during surgery. The selection of the most adequate OVD is especially relevant when performing cataract surgery in challenging cases, such as in hard, mature cataracts, flat anterior chamber, pseudoexfoliation syndrome, intraoperative floppy iris syndrome, or glaucoma surgery. In such cases, OVD is crucial for facilitating the surgical procedure and the associated minimal complication rate. The use of a combination of OVDs (soft-shell technique and modifications), the use of blue-colored OVDs, and the combination of sodium hyaluronate with lidocaine have also been described as useful tools in some of these challenging cases.

Use of viscoelastic substance in ophthalmic surgery - focus on sodium hyaluronate

Among viscoelastic substances, sodium hyaluronate has become the most popular for intraocular surgeries since the introduction of Healon^® (sodium hyaluronate 1%, 4 × 10⁶ daltons) in 1979. This review focuses on the recent development of a new generation of sodium hyaluronate agents with new rheologic properties and the relevant new techniques used in cataract, glaucoma, corneal, and vitreoretinal surgeries. The introduction of sodium hyaluronate agents with different rheologic properties has improved the safety and reliability of intraocular surgeries. Although there have been numerous studies reporting the effectiveness of viscoelastic substances in intraocular surgeries, rigorous validation by multi-center randomized control trials is lacking in many cases. At present, no single viscoelastic agent is most suitable to all of the various intraocular surgical techniques. Therefore, ophthalmologic surgeons should keep up with recent developments of viscoelastic agents and relevant surgical techniques for better patient care.

Viscoanaesthesia in cataract surgery: a prospective, randomized clinical trial

PURPOSE

We aimed to compare viscoanaesthesia (VisThesia) with intracameral lidocaine in cataract surgery carried out under topical anaesthesia.

METHODS

In this prospective study 98 patients were randomly assigned to receive VisThesia (group 1, n = 49) or 0.5 cc of 1% unpreserved lidocaine (group 2, n = 49). All surgery was carried out by one surgeon using clear corneal technique. Pachymetry, the status of the cornea and anterior chamber, and intraocular pressure (IOP) were checked pre- and postoperatively.

RESULTS

Mean pain scores were 0.12 (maximum: 3) in group 1 and 0.37 in group 2; the difference between the groups was not statistically significant (95% confidence interval [CI] 0.003-0.487; p = 0.05). A total of 48 patients in group 1 (98%) and 49 in group 2 (100%) reported no discomfort or only mild discomfort. No significant differences in flare and cells in the anterior chamber or IOP were found between the two study groups. There was a significantly greater frequency of corneal oedema in group 1 (p = 0.001). Postoperative central corneal thickness values were also significantly higher in group 1 (95% CI 11.64-57.24; p = 0.003).

CONCLUSIONS

Results suggest that viscoanaesthesia provides a level of comfort during cataract surgery under topical anaesthesia similar to that facilitated by intracameral lidocaine. However, patients who are given viscoanaesthesia may have increased risk for postoperative corneal oedema.

Safety and efficacy of two ocular anesthetic methods for phacoemulsification: topical anesthesia and viscoanesthesia (VisThesia)

PURPOSE

VisThesia is a new ophthalmic viscosurgical device (OVD) which has 1% lidocaine combined with 1.5% sodium hyaluronate. This is a prospective evaluation of the safety and efficacy of VisThesia used in association with phacoemulsification.

METHODS

A total of 114 eyes were divided into two groups. Fifty-nine eyes were treated with tetracaine + oxybuprocaine topical anesthesia and DuoVisc OVD and 55 eyes were treated with VisThesia, for use as both topical anesthetic and OVD. Endothelial cell counts were measured at 30 days postoperatively and compared to preoperative baseline values. Pain and discomfort was subjectively evaluated by patients using a visual analog pain scale (0-10).

RESULTS

All surgeries were uneventful with no intraoperative or immediate postoperative complications. Patients receiving topical anesthesia had a mean pain score of 1.1+/-6.8 compared to a mean score of 1.3+/-4.6 for patients receiving VisThesia (p=0.59). Postoperatively, endothelial cell loss at 1 month was greater for patients receiving VisThesia (20.32%+/-43.75) than for those receiving the topical anesthetic (8.8%+/-59.6; p<0.0001).

CONCLUSIONS

The results from the visual analog pain scale were comparable between groups, showing that VisThesia provides similar pain relief to topical anesthesia. Specular microscopy performed at 30 days postoperatively showed a significantly greater loss of endothelial cells with the use of VisThesia, suggesting that the 1% lidocaine concentration used in VisThesia may be toxic to corneal endothelial cells.

Clinical evaluation of endothelial cell decrease with VisThesia in phacoemulsification surgery

PURPOSE

To assess the endothelial cell decrease after the use of sodium hyaluronate 0.3% and lidocaine hydrochloride 2% (VisThesia) to determine whether the addition of lidocaine 1% to sodium hyaluronate 1.5% makes the solution more toxic to the cornea.

SETTING

Instituto de Oftalmologia Avanzada, Madrid, Spain, and Unita Operative Oculistica, Cesena, Italy.

METHODS

VisThesia is an ophthalmic viscosurgical device (OVD) that incorporates lidocaine 1% to provide better comfort to patients under topical anesthesia. Fifty eyes 50 patients were operated on following the same patient selection and surgical technique. After the povidone-iodine (Betadine) ocular asepsis, 1 full ampoule of VisThesia Topical was applied over the corneal surface. The intracameral product was used as a routine OVD during the phacoemulsification procedure. The endothelium of the central cornea was examined preoperatively and 3 months after surgery using a noncontact endothelium microscope.

RESULTS

At the last follow-up visit, the mean best corrected visual acuity was 0.88 +/- 0.18 and the mean manifest SE was -0.36 +/- 1.78 D. The mean endothelial cell density had decreased from 2363.57 +/- 435.4 cells/mm2 preoperatively to 2222.6 +/- 537.69 cells/mm2 at 3 months. These values are comparable with results obtained in other investigations published in the literature using other, similar OVD.

CONCLUSIONS

The results observed in this investigation indicate that the addition of lidocaine to the sodium hyaluronate in VisThesia does not induce additional toxicity nor does it result in increased endothelial cell loss when compared with other, similar OVDs.

Evaluation of the cataractogenic effect of viscoanesthetic solutions on the rabbit crystalline lens

PURPOSE

To evaluate the toxicity and cataractogenic effect of solutions combining sodium (Na) hyaluronate 1.0% and 1.5% with lidocaine 1.0% on the rabbit crystalline lens. The amount of pupil dilation provided by the addition of lidocaine to the Na hyaluronate solutions was also assessed.

SETTING

John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.

METHODS

Five solutions were injected into the anterior chamber of 18 pigmented rabbits in a randomized manner by the same surgeon, the intraocular component of VisThesia (Na hyaluronate 1.5%/lidocaine 1.0%), the intraocular component of VisThesia Light (Na hyaluronate 1.0%/lidocaine 1.0%), Ophthalin Plus (Na hyaluronate 1.5%), and a balanced salt solution; and both eyes of 2 other rabbits were injected with nonpreserved aqueous lidocaine 1.0%. The pupil diameter of each eye was measured before injection, immediately after, and 1 and 5 minutes after injection. After a follow-up of 3 months with slitlamp examinations, the rabbits were killed, and their eyes were enucleated. The crystalline lenses were evaluated from a posterior or Miyake-Apple view, and the eyes were fixated in 10% formalin for histopathologic analyses.

RESULTS

Pupil diameter was significantly larger 1 and 5 minutes after injection in the VisThesia (P = .01 and P = .007) and VisThesia Light (P = .008 and P = .007) groups, whereas the differences were not significant in the Ophthalin Plus (P = .317 and P = .102) and balanced salt solution groups (P = .317 and P = .180). Fast and large pupillary dilation was observed in the aqueous lidocaine group, starting during the injection. No differences in the transparency of the natural lens and the red fundus reflex were noted during slitlamp examinations. Postmortem analyses from a posterior view also showed no differences in the transparency of the crystalline lens. The histopathologic appearance of the lens capsule, anterior and equatorial lens epithelial cells, and epithelial lens bow was comparable in the eyes, without signs of cell vacuolization or disruption.

CONCLUSIONS

Intracameral injection of the solutions used in this study caused no localized opacity or overall change in the transparency of the crystalline lenses as observed during clinical and postmortem examinations as well as histopathologic analyses of the enucleated rabbit eyes. Viscoanesthesia may have application in phakic intraocular lens implantation.

Experimental evaluation of the Corneal Concept 360 intraocular lens with the Miyake-Apple view

PURPOSE

To evaluate a new single-piece, hydrophilic acrylic intraocular lens (IOL) designed to keep the anterior capsule away from the IOL optic, create the effect of a capsular tension ring, and prevent posterior capsule opacification (PCO).

SETTING

John A. Moran Eye Center, University of Utah, Salt Lake City, Utah, USA.

MATERIALS AND METHODS

Four Concept 360 IOLs (Corneal Laboratoire) were implanted in 4 human cadaver eyes of various sizes (Miyake-Apple technique). Lens centration, ovalization of the capsular bag and capsulorhexis opening, distance between the anterior optic surface and the anterior capsule and between the posterior optic surface and the posterior capsule, as well as presence of capsular striae were evaluated. The capsular bag was stained with trypan blue, and the ophthalmic viscosurgical device (OVD) was stained with fluorescein to enhance visualization.

RESULTS

In each eye, the lens conformed to the capsular bag with precise centration. No ovalization or distortion of the capsular bag or the capsulorhexis and no posterior capsule striae were observed. Measurements of the capsulorhexis diameter before and after IOL implantation were the same. The anterior capsule remained at distance from the anterior optic surface for 360 degrees, and tight contact between the posterior optic edge and the posterior capsule was observed.

CONCLUSIONS

Use of the Miyake-Apple technique is useful in the evaluation of new IOL designs in experimental studies. Design features of the Concept 360 IOL are likely to decrease the outcome of postoperative capsular bag opacification. Long-term clinical studies are necessary to confirm these findings.

Survey of ophthalmic viscosurgical devices

PURPOSE OF REVIEW

Cataract treatment is evolving, thanks to new phaco systems and innovative surgical techniques. Recent ophthalmic viscosurgical devices (OVDs) play an important role in the development of new approaches to surgery. Knowledge of the new techniques and advances in new OVDs is crucial to performing routine and complicated surgeries.

RECENT FINDINGS

Viscoadaptive substances have been introduced as a particular kind of OVD and are distinguished by high viscosity at a low flow rate and a tendency to fracture at higher flow rates, assuming pseudodispersive behavior. The ultimate soft shell technique emphasizes the rheology of viscoadaptive OVDs to perform phacoemulsification procedures, exploiting all the useful properties of these OVDs in terms of space maintenance and tissue protection. Recent studies have highlighted some new and interesting aspects of the use of OVDs. Current reports suggest that the association of lidocaine and OVD seems to be safe and useful in providing anesthesia during cataract surgery. Concern has been expressed in other studies regarding the presence of contaminants, such as endotoxins, which may be responsible for postoperative uveitis-like reactions. Finally, OVDs are widely known to protect the corneal endothelium during cataract surgery. Their role is also assuming relevance in vitreoretinal surgery.

SUMMARY

New OVDs and related techniques represent an advancement in cataract surgery.

Viscoanesthesia. Part I: toxicity to corneal endothelial cells in a rabbit model

PURPOSE

To evaluate the toxicity of a solution combining sodium hyaluronate 1.5% with lidocaine (0.5%, 1.0%, or 1.65%) to the rabbit corneal endothelium.

SETTING

Center for Research on Ocular Therapeutics and Biodevices, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, USA.

METHODS

Each rabbit cornea was excised, and the endothelium was exposed to 1 of the following solutions for 20 minutes: viscoanesthetic solution (0.5%, 1.0%, or 1.65% lidocaine in sodium hyaluronate 1.5%; 5 corneas each), sodium hyaluronate 1.5% (n = 5), balanced salt solution (BSS(R)) (n = 5), mitomycin-C 0.02% (n = 2), dextran 15% (n = 2), or distilled water (n = 2). The endothelium was then stained with trypan blue and alizarin red. Two corneas were stained immediately after excision. Cell morphology and damage to the corneal endothelium were analyzed by microscopic examination.

RESULTS

The endothelium in the corneas of the viscoanesthetic groups was comparable to that in the sodium hyaluronate 1.5% and the BSS groups and to the corneas not exposed to any solution. In some areas of the 1.0% and the 1.65% viscoanesthesia groups, the corneal endothelial cells presented irregular intercellular borders. Staining with trypan blue, which indicates cellular damage, was observed in some linear areas corresponding to corneal folds in all groups. The folds were probably caused during manipulation for corneal excision and staining. The corneal endothelium was destroyed in the mitomycin group. In the dextran and distilled-water groups, morphological alterations probably resulting from osmotic changes were observed.

CONCLUSIONS

The 3 concentrations of viscoanesthetic solutions appeared to be safe to rabbit corneal endothelium.

Viscoanesthesia. Part II: toxicity to intraocular structures after phacoemulsification in a rabbit model

PURPOSE

To investigate the toxicity of a solution that combines sodium hyaluronate 1.5% with lidocaine (0.5%, 1.0%, or 1.65%) to intraocular structures.

SETTING

Center for Research on Ocular Therapeutics and Biodevices, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, USA.

METHODS

Phacoemulsification was performed in both eyes of 29 rabbits. They were divided into 3 groups; in each group (n = 7), 1 viscoanesthetic solution was used before capsulorhexis. After irrigation/aspiration, 0.2 mL of the solution was purposely left in the capsular bag. In 1 rabbit in each group, the solution was injected into the vitreous cavity through a posterior capsulorhexis. In 8 rabbits used as controls, balanced salt solution (BSS(R)) (n = 4) or sodium hyaluronate 1.5% (n = 4) was injected into the vitreous cavity. Enucleations were performed 15, 30, and 60 days postoperatively. Histological sections were cut and stained with hematoxylin-eosin, periodic acid-Schiff, and Masson trichrome stains.

RESULTS

Light microscopic evaluation of the eyes enucleated after 15, 30, and 60 days in the study and control groups showed similar findings in intraocular structures such as the ciliary body and retina. No evidence of an inflammatory reaction, cell necrosis, or cell degeneration was observed in the histological sections.

CONCLUSIONS

The use of viscoanesthesia during phacoemulsification appeared to be safe, with no histologic abnormalities observed with the 3 lidocaine concentrations. The efficacy of the anesthetic effects of these solutions will be addressed in clinical trials.